Reference trademark issue [Regulatives / Guidelines]

posted by rajasekharkakarla – India, 2018-07-24 11:05 (2482 d 01:16 ago) – Posting: # 19087
Views: 3,264

Dear All,

I prepared protocol for Mesalamine delayed-release tablets 1.2 gm for USFDA submission, i written reference name as Lialda™ (mesalamine) delayed release tablets 1.2 gm with trademark TM and the protocol was approved by EC. But as per COA it is mentioned as Lialda®, there is change in trademark. kindly suggest whether i need to go with ammendment/not.

Regards'
Kakarla

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
116 visitors (0 registered, 116 guests [including 7 identified bots]).
Forum time: 12:22 CEST (Europe/Vienna)

We should not speak so that it is possible
for the audience to understand us,
but so that it is impossible
for them to misunderstand us.    Quintilian

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5